Rapid transitional response to the COVID-19 pandemic by opioid agonist treatment programs in Ukraine.
J Subst Abuse Treat
; 121: 108164, 2021 02.
Article
in English
| MEDLINE | ID: covidwho-952287
ABSTRACT
On March 16, 2020, Ukraine's Ministry of Health issued nonspecific interim guidance to continue enrolling patients in opioid agonist therapies (OAT) and transition existing patients to take-home dosing to reduce community COVID-19 transmission. Though the number of OAT patients increased modestly, the proportion receiving take-home dosing increased from 57.5% to 82.2%, which translates on average to 963,952 fewer clinic interactions annually (range 728,652-1,016,895) and potentially 80,329 (range 60,721-84,741) fewer hours of in-person clinical encounters. During the transition, narcologists (addiction specialists) expressed concerns about overdoses, the guidance contradicting existing legislation, and patient dropout, either from incarceration or inadequate public transportation. Though clinicians did observe some overdoses, short-term overall mortality remained similar to the previous year. As the country relaxes the interim guidance, we do not know to what extent governmental guidance or clinical practice will change to adopt the new guidance permanently or revert to pre-guidance regulations. Some future considerations that have come from COVID-19 are should dosing schedules continue to be flexible, should clinicians adopt telehealth, and should there be more overdose education and naloxone distribution? OAT delivery has improved and become more efficient, but clinicians should plan long-term should COVID-19 return in the near future. If the new efficiencies are maintained, it will free the workforce to further scale up OAT.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Buprenorphine
/
Opiate Substitution Treatment
/
COVID-19
/
Analgesics, Opioid
/
Methadone
/
Opioid-Related Disorders
Type of study:
Prognostic study
Topics:
Long Covid
Limits:
Humans
Country/Region as subject:
Europa
Language:
English
Journal:
J Subst Abuse Treat
Journal subject:
Substance-Related Disorders
Year:
2021
Document Type:
Article
Affiliation country:
J.jsat.2020.108164
Similar
MEDLINE
...
LILACS
LIS